Mip3a/relMtb
Candidate Overview
The Mip3a/relMtb vaccine is an intranasal therapeutic DNA fusion vaccine encoding the M. tuberculosis stringent response antigen relMtb (Rv2583c) linked to the immature dendritic cell–targeting chemokine Mip3a/CCL20, formulated as a plasmid DNA construct without an added adjuvant.